Meeting
2018 ASCO Annual Meeting
Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal canal carcinoma.
Authors
Luc Cabel
Institut Curie, Paris, France
Luc Cabel , Emmanuelle Jeannot , Ivan Bieche , Sophie Vacher , Celine Callens , Alice Bernard , Adeline Morel , Astrid Lièvre , Joelle Otz , Mathieu Minsat , Louis Bazire , Jean-Yves Pierga , Bruno Buecher , Pascale Mariani , Francois Clement Bidard , Wulfran Cacheux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Anal Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3565)
DOI
10.1200/JCO.2018.36.15_suppl.3565
Abstract #
3565
Poster Bd #
58
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dynamic cell free HPV DNA is an early measure of treatment responsiveness in patients receiving induction chemotherapy for HPV-related head and neck cancer.
First Author: Linda (Yilin) Cao
Poster
2020 ASCO Virtual Scientific Program
HPV ctDNA analysis in unresectable recurrent/metastatic oropharyngeal cancer.
First Author: Catherine T Haring
Poster
2023 ASCO Annual Meeting
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
First Author: Peter John Oppelt
Poster
2023 ASCO Annual Meeting
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
First Author: Enrique Sanz Garcia